| 國立成功大學 |
2024-08 |
Agalactosyl IgG induces liver fibrogenesis via Fc gamma receptor 3a on human hepatic stellate cells
|
Ho;Cheng-Hsun;Chang;Ting-Tsung;Lin;Hsien-Chang;Wang;Sheng-Fan |
| 國立成功大學 |
2024-08 |
Impact of long-term treatment with continuous tenofovir alafenamide (TAF) or after switch from tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)
|
Lim;Young-Suk;Wong;Grace;Ahn;Hoon, Sang;Seto;Kay, Wai;Agarwal;Kosh;Janssen;Harry;Pan;Calvin;Chuang;Long, Wan;Fung;Scott;Shalimar;Dr;Brunetto;Maurizia;Hui;Josun, Aric;Chang;Ting-Tsung;Lim;Gee, Seng;Abramov;Frida;Flaherty;John;Wang;Hongyuan;Yee;Leland;Kao;Jia-Horng;Marcellin;Patrick;Gane;Edward;Buti;Maria |
| 國立成功大學 |
2024-07 |
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
|
Yuen;Man-Fung;Chuang;Wan-Long;Peng;Cheng-Yuan;Jeng;Wen-Juei;Su;Wei-Wen;Chang;Ting-Tsung;Chen;Chi-Yi;Hsu;Yao-Chun;Rosa, De La;Guy;Ahmad;Alaa;Luo;Ed;Conery;Annie, L. |
| 國立成功大學 |
2024-01-20 |
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
|
Rimassa;Lorenza;Li;Daneng;Ikeda;Masafumi;Yarchoan;Mark;Ryoo;Baek-Yeol;Kossler;Thibaud;Lim;Ho-Yeong;Kwiatkowski;Mariusz;Chang;Ting-Tsung;Kim;Hyun, Jee;Casadei-Gardini;Andrea;Kudo;Masatoshi;Ren;Zhenggang;Calvo;Varela, Maria;Llovet;Josep, M.;Zhang;Yayan;Hatogai;Ken;Siegel;Abby, B.;Cheng;Ann-Lii |
| 國立成功大學 |
2023-07-10 |
The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer
|
Hsiao;Kai-Ching;Ruan;Siou-Ying;Chen;Shih-Min;Lai;Tai-Yu;Chan;Ren-Hao;Zhang;Yan-Ming;Chu;Chien-An;Cheng;Hung-Chi;Tsai;Hung-Wen;Tu;Yi-Fang;Law;Brian, K.;Chang;Ting-Tsung;Chow;Nan-Haw;Chiang;Chi-Wu |
| 國立成功大學 |
2023-04-29 |
Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan
|
Wu;Juei-Seng;Lin;Yih-Jyh;Chang;Ting-Tsung;Wang;Chung-Teng;Liu;Wen-Chun;Hsieh;Ming-Tsung;Wu;I-Chin;Chen;Po-Jun;Chen;Chiung-Yu;Lin;Sheng-Hsiang;Chuang;Chiao-Hsiung;Han;Meng-Zhi;Chen;Huang-Pin;Tsai;Hong-Ming;Kuo;Hsin-Yu |
| 國立成功大學 |
2023-02 |
Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
|
Chiang;Hsueh-Chien;Lee;Yang-Cheng;Chang;Ting-Tsung;Lin;Yih-Jyh;Wu;Hung-Tsung;Wang;Chung-Teng;Chen;Chiung-Yu;Chen;Po-Jun;Hsieh;Ming-Tsung;Lin;Sheng-Hsiang;Chen;Shang-Hung;Chuang;Chiao-Hsiung;Wu;I-Chin;Hong;Tzu-Chun;Wu;Juei-Seng;Han;Meng-Zhi;Chen;Wei-Ting;Chiang;Chien-Ming;Hung;Kuan-Kai;Kuo;Hsin-Yu |
| 國立成功大學 |
2022-11 |
Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
|
Kuo;Hsin-Yu;Han;Meng-Zhi;Liao;Chih-Hsiang;Lin;Yih-Jyh;Wang;Chung-Teng;Chen;Shang-Hung;Chang;Ting-Tsung;Chen;Po-Jun;Lin;Sheng-Hsiang;Chen;Chiung-Yu;Chuang;Chiao-Hsiung;Wu;I-Chin;Wu;Juei-Seng;Hong;Tzu-Chun;Hsieh;Ming-Tsung;Lee;Yang-Cheng;Wu;Hung-Tsung;Tsai;Hong-Ming |
| 國立成功大學 |
2022-08 |
The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
|
Tseng;Chih-Wei;Liu;Wen-Chun;Ko;Ping-Hung;Chen;Yen-Chun;Tseng;Kuo-Chih;Chang;Ting-Tsung |
| 國立成功大學 |
2021-08 |
Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients
|
Lin;Selena, Y.;Chang;Ting-Tsung;Steffen;Jamin, D.;Chen;Sitong;Jain;Surbhi;Song;Wei;Lin;Yih-Jyh;Su;Ying-Hsiu |
